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Abstract
Background: Utilization of somatic healthcare services is highly predictive of the development of chronic physical
illnesses and increased mortality risks. The objective of this study was to assess the differences in healthcare utilization
among patients with schizophrenia spectrum disorders (SSD), major depressive disorder (MDD) and posttraumatic
stress disorder (PTSD) and the general population in Croatia.
Methods: We enrolled 566 Croatian participants from the general population, 282 with SSD, 178 with MDD, and 86
with PTSD. The primary outcome was a self-reported specialist consultation for non-psychiatric (e.g., somatic) causes
within the previous 12months.
Results: Although SSD patients with chronic physical illnesses were significantly more often hospitalized for physical
illness than the general population, the proportion of patients who had a specialist consultation were equal in SSD and
the general population. MDD and PTSD patients had significantly higher adjusted odds for specialist consultation than
the general population and SSD patients (MDD compared to SSD: OR = 2.14; 95% CI 1.27–3.59; PTSD compared to SSD:
OR = 2.03; 95% CI 1.00–4.10).
Conclusions: SSD patients’ utilization of somatic healthcare is equal to the general population, despite their increased
healthcare needs. However, their utilization is lower than in MDD and PTSD patients and, therefore, probably not
adequate.
Trial registration: The study protocol was registered at ClinicalTrials.gov (NCT02773108) on May 16, 2016.
Keywords: Schizophrenia spectrum disorder, Major depressive disorder, Posttraumatic stress disorder, General
population, Specialist health care utilization
Introduction
It has been known for over two decades that the lifespan
of persons with schizophrenia spectrum disorder (SSD) is
reduced for 15–20 years, [1] primarily due to a high preva-
lence of common preventable and/or treatable chronic
physical illnesses (CPI) and poor primary care utilization.
[2–6] However, even in three Scandinavian countries that
provide among the best-quality and most equitably dis-
tributed healthcare in the world, this mortality gap has
narrowed only by a modest extent and remains stubbornly
wide. [7, 8] Croatia has a universal healthcare system, its
population is covered by a basic health insurance plan pro-
vided by statute and optional insurance administered by the
Croatian Health Insurance Fund (CHIF). This means that
every citizen has the same accessibility to healthcare. [9]
The comorbidity of SSD and CPI has been demonstrated in
studies indicating that individuals with SSD are at signifi-
cantly increased risk of developing CPI, at an earlier age
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due to both maladaptive health risk behaviors, such as
smoking and sedentary lifestyle, and the physiological ef-
fects of their psychiatric illnesses. [10–12] Furthermore, the
CPI may affect treatment outcomes in SSD and are associ-
ated with increased costs. [13–16] It is thus essential not
only to manage the symptoms of schizophrenia but also to
treat comorbid physical illnesses [17] as physical healthcare
needs of SSD patients are elevated. Some studies indicated
that the access and utilization of different non-psychiatric
health care services in this population is below the general
population (GEP). [18–20] However, other studies con-
cluded that no relevant differences in the frequency of SSD
patients’ contacts with healthcare professionals exist [21],
but that the patterns of health care utilization are different.
It was hypothesized that SSD patients have higher rates of
hospitalizations although no more frequent contacts with
primary and secondary care clinicians. The higher rates of
hospitalizations were explained by the delayed first presen-
tation to primary care resulting in patients’ medical condi-
tions being at a more advanced stage, necessitating
hospitalization. [6] Finally, at least one study found that a
higher number of CPI comorbid to SSD may even be asso-
ciated with a better quality of health care. [22] The most
common approach in comparing health care utilization and
the quality of care in SSD patients is the direct comparison
of health care utilization or quality measures. For example,
the annual frequency of specialist consultations between
SSD and GEP is directly compared. However, due to the
higher health care needs of SSD population, this approach
may lead to erroneous conclusions. Several studies have
found the apparent paradox of equality of health services
between SSD patients and GEP, but still premature SSD pa-
tients’ mortality. [23, 24] Therefore, the equality of health
care utilization between SSD and GEP should be interpreted
as an inadequate assessment of SSD patients’ medical
healthcare needs. The methodological difficulty with such
an approach is in defining the optimal health care utilization
levels in SSD. We used a surrogate solution and included
two additional control groups besides GEP: a group of pa-
tients diagnosed with major depressive disorder (MDD) and
a group diagnosed with posttraumatic stress disorder
(PTSD). Our rationale was that SSD patients’ physical
healthcare needs are not lower than in these two psychiatric
patient groups. We hypothesized that the targeted “optimal”
health care utilization level should not only be higher than
in GEP but equal to or higher than in MDD and PTSD.
The objective of our analysis was to assess the differences in
health care utilization between SSD patients and GEP, com-
pared to patients diagnosed with MDD and PTSD.
Methods
Study design
We performed this analysis on the samples from two cross-
sectional studies. The first one was the prospective cohort
study named “Somatic Comorbidities in Psychiatric Pa-
tients (SCPP),” and was performed at Psychiatric Hospital
“Sveti Ivan”, Zagreb, Croatia in 2016. The study protocol
was registered at ClinicalTrials.gov (NCT02773108) and
was approved by the Ethics Committee of Psychiatric Hos-
pital “Sveti Ivan.” All patients signed an informed consent
form. The study complied with the World Medical As-
sociation Declaration of Helsinki 2013. [25] The sec-
ond study was a European health interview survey
(EHIS) conducted for the first time in the Republic of
Croatia between 2014 and 2015, as in all EU Member
States, Iceland and Norway according to the European
Commission Regulation 141/2013 [26, 27].
Study population
The study populations were patients diagnosed with SSD
(ICD-10, F20-F29), MDD (ICD-10, F32–33, and PTSD
(ICD-10, F43.1) (Using the clinical ICD-10 psychiatric
diagnosis coded as the principal diagnosis), treated in the
psychiatric hospital, and the GEP with the permanent resi-
dency in the city of Zagreb and Zagreb County, living in
private households. Psychiatric Hospital “Sveti Ivan”
covers the same geographic region, although a smaller
number of patients came from other parts of the country.
The inclusion criteria common to all four targeted popula-
tions were: age 18–65. The common exclusion criteria
were the inability to answer the questionnaires by them-
selves. The exclusion criteria for the sample from the psy-
chiatric population were dementia, mental retardation,
acute psychosis, and intoxication.
Sample types
Samples from SSD, MDD and PTSD populations were
one-stage consecutive samples. We consecutively in-
cluded all patients, that is the entire available population
of patients who satisfied the inclusion and exclusion cri-
teria and who were present at the hospital during the
enrollment period, either because of being hospitalized
or because they came for an outpatient examination. For
the general population sample, we used a two-stage,
stratified random sample from the EHIS study. The sam-
ple frame was based on the Croatian Census 2011 and
was designed by the Croatian Bureau of Statistics [26,
27]. The primary sampling unit was the household.
Within each household, all present household members
were interviewed. Because the members of the same
household are not independent concerning our out-
comes, the design effect should be assessed. As large
number of primary sampling units was selected (more
than 600 households), the design effect on the effective
sample size was negligible. The overall response rate in
EHIS study was 83%. The sociodemographic structure of
non-responders was not available to us. The response
rate in the study on psychiatric patients was 94%.
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Outcomes
The primary outcome was the self-reported specialist con-
sultation for non-psychiatric causes, experienced within
12months prior to enrollment. The question was phrased
in the same way, and according to the EHIS questionnaire:
“When was the last time you consulted a medical special-
ist because of your needs?” Secondary outcomes were self-
reported measurements of blood pressure, cholesterol,
blood glucose, pap cervical screening and mammography
during the 12months before the enrollment, use of non-
psychiatric medicines within 2 weeks before the enroll-
ment, and the hospitalization because of physical illness
during the previous 12months. These questions were
phrased according to the EHIS questionnaire: “When was
the last time that a healthcare professional measured your
blood pressure…blood cholesterol…etc”.
Independent variable
The independent variable was a psychiatric diagnosis
(SSD, MDD, PTSD), and the GEP. When the patient had
both SSD and MDD or PTSD and MDD comorbidities,
we grouped her/him according to the main diagnosis
and counted the other one only in the number of psychi-
atric comorbidities. We defined the “main diagnosis” as
the older one, the one that was diagnosed first.
Possible confounders
Pre-planned confounders whose effects we controlled by
the multivariable analysis were gender, age, marital sta-
tus, working status, body mass index, self-perceived gen-
eral health, self-reported hospitalization for physical
illness during the 12 months before the enrollment, and
number of CPI. We operationalized the CPI according
to EHIS questionnaire where the participants were asked
about 15 CPI: 1) asthma (allergic asthma included), 2)
chronic bronchitis, chronic obstructive pulmonary dis-
ease, emphysema, 3) myocardial infarction (heart attack)
or chronic consequences of myocardial infarction, 4)
coronary heart disease or angina pectoris, 5) high blood
pressure (hypertension), 6) cerebrovascular insult (cere-
bral hemorrhage, cerebral thrombosis) or chronic conse-
quences of stroke, 7) arthrosis (arthritis excluded), 8)
low back disorder or other chronic back defects, 9) neck
disorder or other chronic neck defects, 10) diabetes mel-
litus, 11) allergy, such as rhinitis, hay fever, eye inflam-
mation, dermatitis, food allergy or other allergies
(allergic asthma excluded), 12) cirrhosis of the liver, 13)
urinary incontinence, problems in controlling the blad-
der, 14) kidney disease, 15) obesity defined as body mass
index (kg/m2) ≥30.0. [26] Data were collected by self-
completion of the 2nd wave European Health Interview
Survey (EHIS). [26] The chronicity of the targeted ill-
nesses was emphasized by the introduction: “Here is the
list of chronic illnesses or conditions”, by show-cards
with the instruction for the respondent written on it:
“Mark with “yes” or “no” for every chronic illness”, and
by the names of CPI that contain the word: “chronic”
when there may be some ambiguity: “chronic bron-
chitis”, “chronic consequences of myocardial infarction”,
“chronic consequences of stroke”, “low back disorder or
other chronic back defects”, “neck disorder or other
chronic neck defects”.
Statistical analysis
The primary analysis was performed using a multivari-
able binary logistic regression in the per-protocol popu-
lation of participants with complete data on the primary
outcome and all pre-planned possible confounders. We
analyzed the differences in available sociodemographic
and clinical characteristics of patients with and without
missing data on the primary outcome and all preplanned
confounders. As the standardized effect size measures,
we presented odds ratios with their 95% confidence in-
tervals (CI). Level of statistical significance was set at a
two-tailed p < 0.05, and all CI was given at the 95% level.
The analysis was carried out using the NCSS 12 Statis-
tical Software (2018) (NCSS, LLC. Kaysville, Utah, USA).
Results
Participants
We assessed 1060 psychiatric patients for eligibility
(Fig. 1). From this sample and the sample of 861 from
the general population, we excluded participants youn-
ger than 18 and older than 65. There were 127 patients
with no data on the primary outcome and pre-planned
possible confounding factors, 67 of them from the gen-
eral population and 60 from the population of psychi-
atric patients. Percentages of non-responders were
similar in the samples from all four targeted populations:
11% in GEP, 10% in SSD and MDD, and 9% in PTSD.
Non-responders were comparable to responders accord-
ing to gender, marital status, and prevalence of obesity.
Median (IQR) age of non-responders and responders
were 40 (33–51) vs 45 (31–55) in GEP, 42 (34–55) vs 40
(32–50) in SSD, 54 (48–57) vs 52 (45–57) in MDD, and
56 (50–62) vs 53 (46–57) in PTSD patients. In GEP
non-responders vs responders there were CPI in 43% vs
57%, in SSD 63% vs 65%, in MDD 74% vs 84%, and in
PTSD 67% vs 91% of cases. Finally, we analyzed 546 psy-
chiatric patients diagnosed with SSD, MDD and PTSD,
and 566 patients from the GEP. In the sample from the
population of patients diagnosed with SSD 113 (40%)
was diagnosed with schizophrenia (ICD-10 F20), 70
(25%) with acute and transient psychotic disorder (ICD-
10 F23), 46 (16%) with unspecified nonorganic psychosis
(ICD-10 F29), 44 (16%) with schizoaffective disorder
(ICD-10 F25) and 9 (3%) with other psychosis. Patients
with PTSD were predominantly war veterans, 72 (84%).
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There were some relevant differences between samples
from our four targeted populations whose possible con-
founding effects we controlled for using a multivariable
analysis (Table 1).
Specialist consultations
The proportion of patients who had a specialist consult-
ation for non-psychiatric reasons was equal in SSD and
GEP (Table 2). After the adjustment for all pre-planned
possible confounding factors, the odds ratio for the con-
sultation was not significantly different between these
two samples. MDD and PTSD patients had significantly
higher adjusted odds for specialist consultation than
GEP (Table 2) and significantly higher adjusted odds
than SSD patients (MDD: OR = 2.14; 95% CI 1.27–3.59;
PTSD: OR = 2.03; 95% CI 1.00–4.10). In patients with
CPI, MDD and PTSD patients had significantly higher
adjusted odds for specialist consultation than GEP with
CPI (MDD: OR = 1.91; 95% CI1.02–3.57 and PTSD:
OR = 2.62; 95% CI 1.06–6.45) (Fig. 2). Both MDD and
PTSD patients had significantly higher adjusted odds for
specialist consultation than SSD patients (MDD: OR =
5.61; 95% CI 2.22–14.21; PTSD: OR = 6.11; 95% CI
1.81–20.58). There were no significant differences in the
odds for specialist consultation between GEP, SSD,
MDD, and PTSD with no CPI (Fig. 2).
Diagnostic and control testing
Compared to 217 (69%) of GEP with CPI who measured
blood pressure at least once during the 12 months before
the enrollment, SSD and MDD patients had higher ad-
justed odds for blood pressure measurement (SSD: OR =
3.61; 95% CI 1.55–8.40; MDD: OR = 5.38; 95% CI 2.01–
14.44). Blood pressure was measured in 73 (87%) of SSD
patients, and 88 (95%) of MDD patients. Measurement
of cholesterol, blood glucose, gynecological pap test or
mammography was not significantly different in any
group with CPI. In patients with no CPI, blood pressure
was measured at least once in 162 (83%) SSD patients,
and they had more than 3.5 times higher adjusted odds
for blood pressure measurement than GEP with no CPI
(OR = 3.61; 95% CI 1.55–8.40). Compared to GEP with
no CPI, SSD and MDD patients had higher adjusted
odds for blood glucose testing (SSD: OR = 3.02; 95% CI
1.79–5.08; MDD: OR = 2.21; 95% CI 1.10–4.44). Blood
glucose tests were performed in 131 (68%) SSD patients
with no CPI. The difference between PTSD and GEP
was not significant (OR = 1.20; 95% CI 0.47–3.11). Simi-
lar results were obtained for cholesterol measurements.
Both MDD and SSD patients had higher adjusted odds
for lipid level assessment compared to GEP (MDD: OR =
2.30; 95% CI 1.38–3.83; SSD: OR = 2.75; 1.38–5.46),
which was performed in 115 (60%) of SSD patients with
no CPI. Again, PTSD patients with no CPI had no
Fig. 1 Participants flow
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Table 1 Participants’ sociodemographic and clinical characteristics
GEP (n = 566) SSD (n = 282) MDD (n = 178) PTSD (n = 86)
Gender
men 263 (46.5) 159 (56.4) 74 (41.6) 72 (83.7)
women 303 (53.5) 123 (43.6) 104 (58.4) 14 (16.3)
Age (years), median (IQR) 45 (31–55) 40 (32–50) 52 (45–57) 53 (46–57)
Education
primary 64 (11.3) 36 (12.8) 20 (11.2) 9 (10.5)
secondary 345 (61.0) 175 (62.1) 114 (64.0) 61 (70.9)
university 157 (27.7) 71 (25.2) 44 (24.7) 16 (18.6)
Marital status
single 165 (29.2) 191 (67.7) 38 (21.3) 17 (19.8)
married 354 (62.5) 58 (20.6) 93 (52.2) 43 (50.0)
widowed or divorced 47 (8.3) 33 (11.7) 47 (26.4) 26 (30.2)
Working status
employed 389 (68.7) 124 (44.0) 103 (57.9) 28 (32.6)
unemployed 77 (13.6) 81 (28.7) 27 (15.2) 12 (14.0)
retired 100 (17.7) 77 (27.3) 48 (27.0) 46 (53.5)
Body mass index (kg/m2), median (IQR) 25 (22–28) 26 (24–30) 27 (24–31) 28 (25–31)
Regular smoking of tobacco 208 (36.7) 161 (57.1) 96 (53.9) 44 (51.2)
Self-perceived general health (bad) 52 (9.2) 44 (15.6) 63 (35.4) 50 (58.1)
Number of physical comorbidities,
median (IQR)a
1 (0–2) 1 (0–2) 2 (1–4) 3 (1–4)
Chronic physical comorbidities
none 268 (47.3) 120 (42.6) 39 (21.9) 12 (14.0)
one 121 (21.4) 70 (24.8) 33 (18.5) 11 (12.8)
two or more (multimorbidity) 177 (31.3) 92 (32.6) 106 (59.6) 63 (73.3)
Being hospitalized for physical
illness during the last 12 months
44 (7.8) 78 (27.7) 54 (30.3) 24 (27.9)
Days of hospitalization for physical illnesses annually, median (IQR)b 4 (2–10) 30 (9–94) 20 (8–90) 10 (2–99)
Status at enrollment
outpatients 125 (44.8) 96 (55.5) 35 (41.7)
in-patients 136 (48.7) 52 (30.1) 39 (46.4)
daily hospital 18 (6.5) 25 (14.5) 10 (11.9)
Duration of primary illness (years), median (IQR) 7 (1–15) 4 (1–8) 10 (4–15)
Psychiatric comorbidity 89 (31.6) 139 (78.1) 73 (84.9)
Previous psychiatric hospitalizations 3 (1–7) 1 (0–3) 3 (1–7)
Psychiatric treatment at enrolment
antipsychotics 262 (92.9) 69 (38.8) 43 (50.0)
antidepressants 109 (38.7) 162 (91.0) 72 (83.7)
benzodiazepines 210 (74.5) 162 (91.0) 83 (96.5)
Data are presented as number (percentage) of participants if not stated otherwise
Abbreviations: GEP general population, SSD schizophrenia spectrum disorder, MDD major depressive disorder, PTSD posttraumatic stress disorder, IQR
interquartile range
aExcluding obesity (BMI ≥ 30)
bOnly participants who were hospitalized at least once
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significantly different adjusted odds for cholesterol test-
ing compared to GEP with no CPI. The interaction of
any study group and current, regular smoking on testing
for blood pressure, cholesterol or blood glucose testing
was not significant. Pap cervical screening and mammog-
raphy were not performed significantly more or less fre-
quently in psychiatric women patients’ samples with no
CPI than in GEP. Pap test was done in 39 (56%) of women
SSD patients with no CPI. Mammography was performed
in 24 (34%) of women SSD patients with no CPI.
Medicines usage
The difference in non-psychiatric medicine usage during
2 weeks before the enrollment was not significantly
different between GEP with CPI: 208 (65%) and SSD: 51
(61%), MDD: 68 (73%) or PTSD patients with CPI: 39
(78%). On this particular sample level, all three psychi-
atric patient groups had non-significantly lower odds for
non-psychiatric medicine usage compared to GEP (SSD:
OR = 0.0.66; 95% CI 0.35–1.23; MDD: OR = 0.83; 95% CI
0.46–1.50; PTSD: OR = 0.74; 95% CI 0.32–1.73).
Hospitalizations for physical illnesses
SSD patients with CPI were significantly more likely to
be hospitalized for physical illness than GEP. Adjusted
odds for at least one hospitalization was almost four
times higher in SSD than in GEP group (OR = 3.96; 95%
CI 2.02–7.76). SSD patients with CPI were hospitalized
Table 2 Consultation with specialists for non-psychiatric illness during the previous 12 months
Had a
consultation
95%
(CI)
Unadjusted Adjusteda, multivariable
OR (95% CI) OR (95% CI) p
GEP 283 (50.0) (46–54) 1 1
SSD 141 (50.0) (44–56)) 1.00 (0.75–1.33) 0.89 (0.61–1.28) 0.520
MDD 132 (74.2) (67–80) 2.87 (1.98–4.17) 1.64 (1.04–2.59) 0.033
PTSD 64 (74.4) (64–83) 2.91 (1.74–4.85) 2.29 (1.20–4.37) 0.012
Gender
men 256 (45.1) (41–49)) 1 1
women 364 (66.9) (63–71) 2.47 (1.93–3.14) 3.01 (2.26–4.02) < 0.001
Age 1.02 (1.01–1.03) 0.99 (0.98–1.01) 0.316
Education
primary 72 (55.8) (47–65) 1 1
secondary 384 (55.3) (52–59) 0.98 (0.67–1.43) 1.13 (0.72–1.78) 0.583
university 164 (56.9) (51–63) 1.05 (0.69–1.59) 1.44 (0.88–2.37) 0.151
Marital status
single 188 (45.7) (41–51) 1 1
married 339 (60.2) (56–64) 1.80 (1.39–2.33) 1.24 (0.84–1.83) 0.284
widowed or divorced 102 (66.7) (59–74) 2.37 (1.61–3.50) 1.20 (0.72–2.01) 0.487
Working status
employed 348 (54.0) (50–58) 1 1
unemployed 101 (51.3) (44–58) 0.90 (0.65–1.23) 0.84 (0.57–1.24) 0.390
retired 171 (63.1) (57–69) 1.45 (1.09–1.95) 0.84 (0.57–1.26) 0.842
Body mass index (kg/m2) 1.04 (1.01–1.06) 1.02 (0.99–1.05) 0.249
Self-perceived general health
good or average 452 (50.1) (47–53) 1 1
bad 168 (80.4) (74–86) 4.09 (2.84–5.89) 2.14 (1.38–3.31) 0.001
Having a CPI 377 (68.3) (64–72) 2.95 (2.30–3.78) 1.76 (1.27–2.45) 0.001
Number of physical comorbidities 1.51 (1.39–1.65) 2.14 (1.38–1.37) < 0.001
Being hospitalized for physical illness during the last 12 months 162 (81.0) (75–86) 4.23 (2.90–6.16) 3.68 (2.40–5.64) < 0.001
Data are presented number (percentage; percentage’s 95% CI) of participants
Abbreviations: OR odds ratio, CI confidence interval, p two-tails statistical significance calculated using multivariable binary logistic regression, GEP general
population, SSD schizophrenia spectrum disorder, MDD major depressive disorder, PTSD posttraumatic stress disorder, IQR interquartile range, CPI chronic
physical illness
aAdjustment was done for: gender, age, marital status, working status, body mass index, self-perceived general health, number of physical illnesses, hospitalization
during the 12months before the enrollment
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in 33 (39%) of cases, and GEP in 40 (13%). The other
two psychiatric groups, MDD and PTSD, were hospital-
ized in 29 (30%), and 18 (35%) respectively. After the ad-
justment for age, gender, education, working and marital
status and body mass index SSD patients with CPI had
significantly higher odds for hospitalization for physical
illness then MDD patients (OR = 0.63; 95% CI 0.42–
0.94), but not compared to PTSD patients (OR = 0.91;
95% CI 0.73–1.14).
Discussion
Although SSD patients with or without CPI have higher
specialist healthcare needs than GEP, our study found that
their specialist physical healthcare utilization is not higher.
This finding is not psychiatric-specific, but SSD specific,
because patients diagnosed with MDD or PTSD use spe-
cialist health care to larger extent than GEP or SSD pa-
tients. SSD patients’ utilization of somatic healthcare is
equal to GEP, despite their increased healthcare needs.
Moreover, this utilization is lower than in MDD and
PTSD patients and, therefore, likely to be inadequate.
Our finding that the hospitalization rate and its me-
dian duration are increased in SSD patients, whereas
their consultation with the specialist is equal or lower
than in GEP, is consistent with the conclusion of previ-
ous studies that SSD patients have different patterns of
health care utilization, not seeking help until their con-
dition requires hospitalization. [21, 24] This delay in
contact with the health care system may be caused by
SSD patients lower ability to interpret the physical
symptoms correctly, lower pain sensitivity caused by an-
tipsychotics [3], lower education and social support, so-
cioeconomic status, self-stigmatization or inactivity, and
loss of initiative due to negative symptoms. [28] If the
health care system requires a patient’s self-initiative to
be fully utilized in order to access care [29] then SSD pa-
tients would not have equal chances for the health care
utilization and CPI treatment when compared to GEP,
or to patients diagnosed with MDD or PTSD whose cog-
nitive executive functioning is less affected by the pri-
mary psychiatric condition. [30] MDD and PTSD
patients also have better socioeconomic status, better so-
cial support, and lower self and social stigmatization.
Also, MDD, PTSD and particularly GEP patients’ quality
of communication with the somatic health care clini-
cians may be superior to the communication skills of
SSD patients [31–33]. On the other hand, the incidence
of MDD is increased in many different medical condi-
tions. [34] Depression and anxiety are the most often
co-occurring mental disorders with medical illnesses and
are independent predictors of worsened outcome in nu-
merous medical conditions including diabetes and car-
diovascular disease. [35] As a consequence, different
somatic medicine specialists are more accustomed to
MDD and more knowledgeable about MDD than about
SSD. Our finding that PTSD, predominantly veteran
population, have the highest utilization of specialist
healthcare is concordant with many other studies show-
ing the higher rates of guideline-concordant care in this
population. [36] The reach, funding, and efficacy of non-
governmental veteran organizations as well as govern-
ment care, are superior to non-medical organizations
aimed at helping patients with SSD in Croatia. Finally,
MDD and PTSD patients, as was shown by our study,
perceive their health status significantly less favorably
than SSD patients, while this perception is the signifi-
cant predictor of specialist consultation, and is associ-
ated with marked increase in use of healthcare. [37]
Fig. 2 Adjusted percentage of participants having a specialist consultation for non-psychiatric illness during the 12months before the enrollment;
error lines represent 95% confidence intervals; adjustment was done for: gender, age, marital status, working status, body mass index, self-
perceived general health, number of physical illnesses, hospitalization during the 12 months before the enrollment
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One of the probable causes of insufficient health care
utilization in SSD population has nothing to do with
SSD, but with the single-disease paradigm. [38] The spe-
cialists, secondary and tertiary healthcare systems are
single-disease focused. Specialists are usually highly
trained in specific medical conditions, the health care
system is fragmented, and multimorbidity requires con-
tacts with different clinicians, different departments or
even hospitals. This approach poses an additional bur-
den on SSD patients who may be less able to cope with
such a demanding diversity, which may affect their ad-
herence [39], that may further complicate the relation-
ship with the clinicians, the most prevalent cause of
psychiatric treatment failure [40, 41], and physical and
mental health care are most often physically separated
[29], and as competent and comprehensive psychiatric
care often cannot be provided in internal medicine facil-
ities, nor can psychiatric institutions provide effective
somatic medicine due to lack of resources. Such a separ-
ation of available services may hinder SSD patients more
than MDD or PTSD patients.
Contrary to some previous studies’ conclusion that
high blood pressure is often missed in several psychiatric
populations [42], we found a higher frequency of blood
pressure monitoring in SSD and MDD patients than in
GEP. This result may be institution-specific as the blood
pressure measurement, and complete blood count is
routinely performed at each hospital admission in Psy-
chiatric Hospital “Sveti Ivan”, where we enrolled the
samples from the psychiatric patient population. Al-
though a significantly higher proportion of SSD patients
than participants from the GEP had their blood glucose
assessed, the absolute magnitude was too low (68%). If
93% of our participants with SSD were treated with anti-
psychotics at the time of enrollment and if 100% would
be treated with these metabolically active drugs, then
the blood glucose and cholesterol measurement should
be routinely and regularly performed in all SSD patients
regardless of CPI. [43]
Limitations of the study
The first limitation of our study was the relatively lower
reliability of our primary outcome which was based on the
self-report questionnaire, and it was not checked inde-
pendently. As the data were limited to the EHIS study
questionnaire, there was no means of excluding this po-
tential source of recall bias. Future studies should use the
more precise and comprehensive measures of specialist
healthcare utilization taking into the account number of
consultations, differences between public and private spe-
cialists’ offices, the reasons and outcomes of these consul-
tations, type of medical specialty, extent and differences of
specialists’ clinical inertia, that is their occasional deviation
from the evidence-based clinical guidelines and the best
practices, as well as stigma, care and use of emergencies.
Second, we based our assumption on the higher specialist
health care needs in SSD than in GEP on participants self-
reports and literature however neither may be adequately
valid and reliable in this particular case. Future studies
should define the specialist’ health care utilization relative
to the objectively measured health care needs. Third, we
treated SSD patients like one, homogenous group,
which is not precisely accurate. Future studies should
differentiate specific SSD diagnosis, the severity of ill-
ness and configuration of symptoms, and assess the
same question more depth. Fourth, we did not record
the data on the substance abuse although it may
moderate the healthcare utilization and may be differ-
ent between our targeted populations.
Fifth, one of the exclusion criteria we used to define the
targeted populations was the participants ability to answer
the questionnaires by themselves. This could exclude pa-
tients with more severe CPI symptoms and with the most
severe presentations of their psychiatric condition. If this
exclusion criterion’s effect on CPI were comparable in our
targeted populations, the selection bias would lower the
generalizability of both of our samples and the precision
of our findings, but not the direction of our main conclu-
sion. If this effect on CPI were stronger in one of our tar-
geted populations, it would jeopardize the internal validity
of the study. This effect on the severity of psychiatric con-
dition in principle may have two different consequences: if
the excluded patients with the most severe mental dis-
order have a higher utilization of somatic healthcare, the
described limitation would enlarge the difference toward
GEP. If the excluded patients utilization of somatic health-
care is lower, this will lower the difference toward GEP.
We could not speculate about the exact direction nor the
magnitude of this effect.
Sixth, we selected the different sample types from the
population of psychiatric patients and the GEP: consecu-
tive and stratified, random respectively. Our consecutive
sample might increase the risk of selection bias and re-
sult in an overrepresentation of the population with bet-
ter access to healthcare. If so, this source of bias would
act in favor of our null hypothesis and increase the risk
of false negative results. We were not able to select the
random sample from the total population of psychiatric
patients, and only new studies performed on random
samples or the consecutive samples but with markedly
longer enrollment period may check and probably cor-
rect this possible source of lower internal validity of our
results. Seventh, we selected the sample from the popu-
lation of psychiatric patients in the large psychiatric hos-
pital in the highly urban capital of Croatia. Therefore,
our results should be cautiously generalized to the popu-
lation treated in smaller provincial hospitals and psychi-
atric wards of the general hospitals in less affluential and
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more rural parts of the country. Eight, despite the fact
that we enrolled the patients in hospital wards, daily
hospitals, and outpatients offices, and that only a min-
imal number of patients with SSD, MDD or PTSD in
Croatia are diagnosed and having their treatments con-
trolled out of the psychiatric hospital, the population of
outpatients was probably somewhat underestimated in
our sample. It is likely that the part of the population
that is missing in our samples have a more severe dis-
order, but possibly also better access to healthcare.
Conclusion
SSD patients’ utilization of somatic healthcare is equal to
the general population, despite their increased healthcare
needs. Moreover, this utilization is lower than in MDD
and PTSD patients and, therefore, likely to be inadequate.
These results raise concerns over the adequacy of physical
health care for patients diagnosed with SSD. Croatia has
universal health coverage that provides more equal oppor-
tunities to access care, so in other healthcare systems, the
observed inequalities may differ. If one aims to control the
increased mortality in SSD population, improve these pa-
tients´ quality of life, and effectively reduce the influence
of CPI on psychosis treatment outcomes, interventions
aimed at facilitating preventive healthcare utilization
should be integrated into psychiatric treatment.
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